- Home
- AGNT vs SCTX Comparison
AGNT vs SCTX Comparison
Compare AGNT & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGNT | SCTX |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 621.7M | 536.5M |
| IPO Year | 2010 | 2026 |
Fundamental Metrics
Financial Performance| Metric | AGNT | SCTX |
|---|---|---|
| Price | $4.14 | $15.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.00 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 1.5M | 415.3K |
| Earning Date | 11-05-2026 | 11-29-2026 |
| Dividend Yield | ★ 4.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,147,681.00 | N/A |
| Revenue This Year | $5.70 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 220.39 | N/A |
| 52 Week Low | $3.40 | $13.50 |
| 52 Week High | $5.79 | $39.60 |
Technical Indicators
Market Signals| Indicator | AGNT | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 33.52 |
| Support Level | $3.52 | $13.50 |
| Resistance Level | $4.79 | $22.07 |
| Average True Range (ATR) | 0.26 | 2.40 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 90.18 | 2.88 |
Price Performance
Historical ComparisonAbout AGNT AGNT Inc. Common Stock
AGNT Inc is a multi-model real estate platform, with brands including eXp Realty, eXp Commercial, NextHome, FrameVR.io, and SUCCESS Enterprises. The group prioritizes transparency, innovation, and long-term value for agents, franchise owners, staff, and shareholders.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.